FIGURE 1.
Live cps treatment causes regression of established dermal B16F10 melanoma by immune effects. (A) cps treatment strategy, each treatment was 1.5×107 tachyzoites of cps injected intratumorally that began when tumors reached 3.5–5mm diameter. (B) Photos of tumors 21 days post challenge. cps treated mice are top panel, PBS treated mice are bottom panel. (C) Individual mouse tumor growth kinetics (left) and survival curve (right) of established primary B16F10 tumor-bearing mice treated with cps or PBS. (D) Tumor growth and survival curve of B16F10 tumor-bearing mice treated with cps or PBS after established latent infection by Toxoplasma gondii (PRU). (E) Tumor growth and survival curve of primary tumor treatment with cps killed by heating at 65°C prior to injection. (F) Tumor growth and survival curve of tumors in NOD/SCID/IL2 gamma receptor KO mice. Error bars are SEM; P values: * < 0.05, ** < 0.01, *** < 0.001, n/s is not statistically significant, n= minimum of 6 per group, data are representative of at least 2 independent experiments.